April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee
Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.
Replimune Receives Complete Response Letter from the FDA
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma. 10 avr. 2026 17h02 HE | ...
Savara Announces the U.S. Food & Drug Administration (FDA) Has ...
Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...
FDA approves nivolumab with chemotherapy for Hodgkin lymphoma
This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...
FDA Schedules Public Meeting on the Commissioner's National ...
... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
